FeesSafety
Pluang+

SEC discusses regulatory treatment for VolMEX's Bitcoin ETF volatility options product

Market News
07 Oct 2026, 20:27 WIB
Tokenpost
View Source
Neutral
SEC discusses regulatory treatment for VolMEX's Bitcoin ETF volatility options product

The U.S. Securities and Exchange Commission met with VolMEX Labs and Clifford Chance to discuss regulatory considerations for a proposed options product linked to Bitcoin ETF volatility. The product would be based on the Volmex Bitcoin ETF Volatility Index, designed to measure real-time implied volatility of Bitcoin ETFs. The meeting covered existing options rules, potential crypto-related structures, and whether new guidance or relief is needed. The product is not yet approved or launched, and the SEC has not publicly indicated any decision, as it continues developing broader crypto regulations.

The VolMEX proposal for Bitcoin volatility options is presented here with Pluang's cryptocurrency market data as context. For readers following digital assets, the breadth on Pluang shows 5 rising and 44 falling out of 50 major cryptocurrencies as of Oct 08, 2026 00:34 WIB. Among these, ENJ fell 8.81% to Rp537 with a 69% sell order activity, contrasting with SUSHI which dropped 8.75% to Rp4.135 but had a dominant 97% buy order activity, while DOT declined 8.69% to Rp19.658 with 65% sell orders and the longest typical hold time of 121 days.

More News

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft to retire UWP Map Control by Nov 2026; OnTerra offers ready replacement using Azure Maps.

Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...

Market News
Neutral
1 hour ago
New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

New combo therapy shows promise in tough metastatic breast cancer cases with high response rates

Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...

Company Fundamentals
Bullish
2 hours ago
Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Deadlines set for lead plaintiff appointments in class action lawsuits against Ensign, Netcapital, and Webull.

Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...

Bearish
2 hours ago
Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave launches Attune Facilities, an AI-driven tool for managing complex multi-site operations efficiently.

Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...

Market News
Bullish
2 hours ago
ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. price target raised to $259 after strong Q3 with 44% revenue growth and 20% earnings rise.

ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App